10 Stocks That Vanished in Value

4. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics tumbled by 9.08 percent on Tuesday to close at $25.68 apiece as investor sentiment was dampened by a dismal earnings performance as well as the absence of an investor call to elaborate on the results.

Summit Therapeutics Inc. (NASDAQ:SMMT), which usually reports its quarterly earnings alongside an investor call, decided go without the latter on Monday.

In the second quarter of the year, Summit Therapeutics Inc. (NASDAQ:SMMT) widened its net loss by 836 percent to $565.7 million from $60.4 million in the same period last year, as total operating expenses soared by 853 percent to $568.4 million from $59.6 million year-on-year.

Net loss in the first half also expanded by 505 percent to $628.6 million from $103.9 million year-on-year, as total operating expenses jumped 522 percent to $635.3 million from $102 million.

Summit Therapeutics Inc. (NASDAQ:SMMT) also skipped to comment on its financial and operating results.